Abstract
Nitroaromatic antibiotics have a long and controversial history in human and veterinary medicine. This controversy lies behind the presumption of many pharmaceutical companies that nitroaromatic compounds should be filtered from the list of drug-like compounds but stands at odds with the remarkably safe clinical record of use of such compounds. In this review, we will describe the whole-cell structure-activity relationships that have been reported for antimycobacterial nitroimidazoles as well as the available in vivo data supporting efficacy with a particular emphasis on nitroimidazo[2,1-b]oxazines such as PA-824. We will also explore the unique potential of such compounds to shorten the course of tuberculosis therapy by exerting a bactericidal effect on non-replicating bacilli. We will consider the mode of action of such compounds in sensitive organisms and discuss the mechanisms by which resistance may emerge. Finally, we will review the pharmacokinetics, toxicology and laboratory and animal studies linking nitroimidazoles with carcinogenicity and mutagenicity and assess the prospects for the clinical introduction of nitroimidazoles for the treatment of tuberculosis.
Keywords: mycobacterium tuberculosis, nitroimidazole, bioreduction, nitroreductase, persistence, anaerobic metabolism, metronidazole, mutagenicity
Current Pharmaceutical Design
Title: Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis
Volume: 10 Issue: 26
Author(s): Clifton E. Barry, Helena I.M. Boshoff and Cynthia S. Dowd
Affiliation:
Keywords: mycobacterium tuberculosis, nitroimidazole, bioreduction, nitroreductase, persistence, anaerobic metabolism, metronidazole, mutagenicity
Abstract: Nitroaromatic antibiotics have a long and controversial history in human and veterinary medicine. This controversy lies behind the presumption of many pharmaceutical companies that nitroaromatic compounds should be filtered from the list of drug-like compounds but stands at odds with the remarkably safe clinical record of use of such compounds. In this review, we will describe the whole-cell structure-activity relationships that have been reported for antimycobacterial nitroimidazoles as well as the available in vivo data supporting efficacy with a particular emphasis on nitroimidazo[2,1-b]oxazines such as PA-824. We will also explore the unique potential of such compounds to shorten the course of tuberculosis therapy by exerting a bactericidal effect on non-replicating bacilli. We will consider the mode of action of such compounds in sensitive organisms and discuss the mechanisms by which resistance may emerge. Finally, we will review the pharmacokinetics, toxicology and laboratory and animal studies linking nitroimidazoles with carcinogenicity and mutagenicity and assess the prospects for the clinical introduction of nitroimidazoles for the treatment of tuberculosis.
Export Options
About this article
Cite this article as:
Barry E. Clifton, Boshoff I.M. Helena and Dowd S. Cynthia, Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis, Current Pharmaceutical Design 2004; 10 (26) . https://dx.doi.org/10.2174/1381612043383214
DOI https://dx.doi.org/10.2174/1381612043383214 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Simple and Green Procedure for the Synthesis of N-Benzylthioureas
Letters in Organic Chemistry Evolution of the DUT Gene: Horizontal Transfer between Host and Pathogen in all Three Domains of Life
Current Protein & Peptide Science Despite an Extensive Sequence Analysis Identification of Functional Candidates Amongst Hypothetical Proteins of Neisseria gonorrhoeae
Letters in Drug Design & Discovery Drug Evolution Concept in Drug Design: 2. Chimera Method
Medicinal Chemistry Molecular Docking, Metal Substitution and Hydrolysis Reaction of Chiral Substrates of Phosphotriesterase
Combinatorial Chemistry & High Throughput Screening RND Efflux Pumps: Structural Information Translated into Function and Inhibition Mechanisms
Current Topics in Medicinal Chemistry Preface
Current Medical Imaging New Pyrrole Hydrazones Synthesized and Evaluated In Vitro as Potential Tuberculostatics
Letters in Drug Design & Discovery Solvent-free Synthesis of Phthalazine-2(1H)-carboxamide Derivatives Using K-10 Clay Under Microwave Irradiation
Letters in Organic Chemistry Molecular Modeling Databases: A New Way in the Search of Protein Targets for Drug Development
Current Bioinformatics The Mechanism by which the Phenothiazine Thioridazine Contributes to Cure Problematic Drug-Resistant Forms of Pulmonary Tuberculosis: Recent Patents for “New Use”
Recent Patents on Anti-Infective Drug Discovery Surfactant Protein (SP)-A and SP-D as Antimicrobial and Immunotherapeutic Agents
Recent Patents on Anti-Infective Drug Discovery Pulmonary Disease in Beta-Thalassemia
Current Respiratory Medicine Reviews Elucidating Unusual Modes of Action and Resistance of Antibacterial Peptides
Current Topics in Medicinal Chemistry Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform
Current Pharmaceutical Design The Use of SIFT-MS in Profiling the Faecal Volatile Metabolome in Horses with Colic: A Pilot Study
Current Analytical Chemistry Human Peroxiredoxins 1 and 2 and Their Interacting Protein Partners; Through Structure Toward Functions of Biological Complexes
Protein & Peptide Letters The Widespread Anti-Protozoal Action of HIV Aspartic Peptidase Inhibitors: Focus on Plasmodium spp., Leishmania spp. and Trypanosoma cruzi
Current Topics in Medicinal Chemistry Chemical Constituents from the Chinese Bryophytes and Their Reversal of Fungal Resistance
Current Organic Chemistry State of the Art of Nanobiotechnology Applications in Neglected Diseases
Current Nanoscience